Literature DB >> 7541671

Tyrosine phosphorylation of the erythropoietin receptor: role for differentiation and mitogenic signal transduction.

S Gobert1, F Porteu, S Pallu, O Muller, M Sabbah, I Dusanter-Fourt, G Courtois, C Lacombe, S Gisselbrecht, P Mayeux.   

Abstract

The erythropoietin (Epo) receptor belongs to the cytokine receptor superfamily. Although the cytokine receptors do not possess a tyrosine kinase consensus sequence in the intracellular domain, rapid stimulation of a tyrosine kinase activity occurs after activation by the ligand. We and others have shown that Epo induces the tyrosine phosphorylation of its cognate receptor as well as phosphorylation of other proteins. In this report, we examined the role of the receptor tyrosine residues in signal transduction. Eight tyrosine residues are located within the intracellular domain of the murine Epo receptor. A single tyrosine residue is present in the region previously shown to be sufficient for proliferative signal transduction. This tyrosine (Tyr 343) was mutated to phenylalanine. Moreover, mutant receptors were also generated with either a tyrosine residue or a phenylalanine residue at position 343 and with a COOH terminal truncation that removed the 7 other tyrosine residues. Expression vectors carrying these mutated receptors were transfected into the interleukin-3-dependent murine cell line Ba/F3. Epo-induced growth was sustained efficiently by all these receptors, although receptors without any tyrosine residues conferred a significantly reduced mitogenic activity. Moreover, all receptors were able to mediate Epo-dependant accumulation of beta-globin mRNA. The mutated receptors all induced the tyrosine phosphorylation of several cellular proteins after Epo stimulation. However, the truncated receptors induced the phosphorylation of a reduced number of proteins, suggesting that phosphorylated tyrosines of the receptor could have a role in the recruitment either of a tyrosine kinase or of tyrosine kinase substrate proteins. The receptors were all able to mediate Epo-induced activation of phosphatidylinositol 3-kinase, although truncated receptors no longer bound phosphatidylinositol 3-kinase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541671

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.

Authors:  K Nishigaki; C Hanson; T Ohashi; D Thompson; K Muszynski; S Ruscetti
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

Authors:  K Okuda; A D'Andrea; R A Etten; J D Griffin
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Design of conditionally active STATs: insights into STAT activation and gene regulatory function.

Authors:  L H Milocco; J A Haslam; J Rosen; H M Seidel
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

4.  Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation.

Authors:  S Chrétien; P Varlet; F Verdier; S Gobert; J P Cartron; S Gisselbrecht; P Mayeux; C Lacombe
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

Review 5.  Structural and functional hot spots in cytokine receptors.

Authors:  C J Bagley; J M Woodcock; M A Guthridge; F C Stomski; A F Lopez
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

6.  Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation.

Authors:  S Gobert; S Chretien; F Gouilleux; O Muller; C Pallard; I Dusanter-Fourt; B Groner; C Lacombe; S Gisselbrecht; P Mayeux
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.